Immatics price target lowered to $14 from $17 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Immatics (IMTX) to $14 from $17 and keeps a Buy rating on the shares. The firm adjusted estimates and targets
16h agoIMTX
Compare Stocks
Compare up to 40 stocks
Compared Stocks: 1 / 40
Comparison Results
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 IMTX | Healthcare | $6.39 | 586.39K | $1.00B | -3.46 | ― | Strong Buy |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IMTX | Immatics | 6.39 | -3.61 | -36.08% |
| Name | Price | % Change | |
|---|---|---|---|
| IMTX | $6.39 | -36.08% |
Custom Stock Latest News
Immatics reports Q3 EPS (EUR 0.50) vs. (EUR 0.42) last yearReports Q3 revenue EUR 6.92M vs. EUR 5.19M last year. “Our focus is clear: completing enrollment in the Phase 3 SUPRAME trial and preparing for the BLA filing for anzu-cel
3d agoIMTX
Immatics Reports Third-Quarter 2026 Results and Business UpdateThe latest update is out from Immatics ( ($IMTX) ). Immatics N.V. and its subsidiaries are presented as a research-and-development group whose report covers product candidates, a research pipeline, preclinical
Immatics price target lowered to $21 from $25 at MizuhoMizuho analyst Graig Suvannavejh lowered the firm’s price target on Immatics (IMTX) to $21 from $25 and keeps an Outperform rating on the shares. Published first on TheFly – the
2w agoIMTX
Immatics Posts Strong PRAME-Targeted Data for IMA402 and IMA203CD8 at 2026 ESMOImmatics ( ($IMTX) ) has shared an update. On October 24, 2026, Immatics released updated Phase 1b data for its IMA402 PRAME TCR bispecific, showing favorable safety and encouraging efficacy
- Immatics announces updated trial data from Phase 1b study of IMA402
Immatics (IMTX) announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy. Key highlights: IMA402
2w agoIMTX 
Immatics Unveils Strong Phase 1 Data for IMA203CD8 in PRAME-Positive Solid TumorsImmatics ( ($IMTX) ) has shared an update. On October 23, 2026, Immatics reported updated Phase 1 data for its IMA203CD8 PRAME-directed TCR T-cell therapy in advanced solid tumors, based
- Immatics initiated with a Buy at Stifel
Stifel initiated coverage of Immatics (IMTX) with a Buy rating and $15 price target The firm views Immatics as “well positioned to be a leader in melanoma” via its PRAME-HLA
1M agoIMTX 
Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer ProgramsImmatics ( ($IMTX) ) just unveiled an announcement. Immatics N.V., a Nasdaq-listed biotech company headquartered in Houston and Tübingen, focuses on developing cancer immunotherapies that precisely target PRAME, an antigen
- Immatics price target lowered to $17 from $18 at Jefferies
Jefferies lowered the firm’s price target on Immatics (IMTX) to $17 from $18 and keeps a Buy rating on the shares. Immatics announced a $150M raise, and the firm caught
2M agoIMTX
Recent Analysts Ratings of Custom Stocks
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| IMTX | buy | Reiterated | Nov 13, 2026 | |||
| IMTX | buy | Reiterated | Oct 29, 2026 | |||
| IMTX | buy | Reiterated | Oct 26, 2026 | |||
| IMTX | buy | Assigned | Aug 25, 2026 | |||
| IMTX | buy | Reiterated | Aug 18, 2026 | |||
| IMTX | buy | Reiterated | Aug 18, 2026 | |||
| IMTX | buy | Reiterated | May 19, 2026 | |||
| IMTX | buy | Reiterated | May 12, 2026 | |||
| IMTX | buy | Reiterated | Mar 6, 2026 | |||
| IMTX | buy | Reiterated | Dec 11, 2025 |
Most Recent Earnings of Custom Stocks
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| IMTX | Mar 24, 2027TBA | $1.00B | $-0.57 | $9.38M | 0.00 | -3.46 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
- Comprehensive Analysis: Compare up to 40 stocks with detailed metrics including price, market cap, P/E ratio, dividend yield, and more.
- Analyst Ratings: View consensus ratings from top Wall Street analysts and their price targets for each stock.
- Performance Tracking: Analyze historical performance with interactive charts showing 3-month, 6-month, 1-year, YTD, 3-year, and 5-year returns.
- Dividend Information: Evaluate dividend yield, payout ratio, and dividend growth for income-focused investors.
- Earnings Data: Compare earnings per share (EPS), revenue growth, and profitability metrics across companies.
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
All Stock Comparison Categories
Custom Stock - FAQ
Which Custom stocks have a "Strong Buy" analyst rating?
These Custom stocks currently have a "Strong Buy" analyst rating consensus: Immatics - Strong Buy, based on 6 analyst ratings, 6 Buy, 0 Hold, and 0 Sell.
Are Custom stocks overpriced?
Immatics's stock price is currently $6.39, and its average 12-month price target is N/A.
Which Custom stocks pay dividends?
Immatics does not currently pay dividends.